[HTML][HTML] Mechanisms of SARS-CoV-2 entry into cells
The unprecedented public health and economic impact of the COVID-19 pandemic caused
by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …
by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is
central to long-term control of the current pandemic. Despite our rapidly advancing …
central to long-term control of the current pandemic. Despite our rapidly advancing …
Convalescent plasma for covid-19–induced ARDS in mechanically ventilated patients
B Misset, M Piagnerelli, E Hoste… - … England Journal of …, 2023 - Mass Medical Soc
Background Passive immunization with plasma collected from convalescent patients has
been regularly used to treat coronavirus disease 2019 (Covid-19). Minimal data are …
been regularly used to treat coronavirus disease 2019 (Covid-19). Minimal data are …
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled …
Although most randomized controlled trials have shown negative results, uncontrolled …
Early convalescent plasma for high-risk outpatients with Covid-19
FK Korley, V Durkalski-Mauldin… - … England Journal of …, 2021 - Mass Medical Soc
Background Early administration of convalescent plasma obtained from blood donors who
have recovered from coronavirus disease 2019 (Covid-19) may prevent disease …
have recovered from coronavirus disease 2019 (Covid-19) may prevent disease …
[HTML][HTML] Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background Many patients with COVID-19 have been treated with plasma containing anti-
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European …
S Cesaro, P Ljungman, M Mikulska, HH Hirsch… - Leukemia, 2022 - nature.com
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …
Antibody-mediated neutralization of SARS-CoV-2
Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …
Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …
in patients with viral respiratory diseases, and are currently being investigated in trials as …